<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501213</url>
  </required_header>
  <id_info>
    <org_study_id>DIASC-1507</org_study_id>
    <nct_id>NCT02501213</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)</brief_title>
  <official_title>A Randomized Cross-over Trial Evaluating the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Palliative Stage of Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While some authors recommend diuretics as the first treatment to initiate for symptoms caused
      by malignant ascites (MA), their prescription is variable. No randomized, controlled study
      has assessed their benefit in this context. According to literature, diuretics may bring
      relief in about 40% of cases, regardless of primary tumor.

      The purpose of our study is to assess the effectiveness of diuretic treatment according to
      Serum Ascites Albumin Gradient (SAAG) measured before treatment. Judgment criteria is the
      time elapsed between recurrent MA that requires paracentesis. The investigators will also
      examine whether SAAG and serum levels of renin and aldosterone can predict symptom response
      to diuretics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients eligible for the trial and having signed their consent to participate will be
      randomized to arm A or B.

      Treatment order is randomly attributed to patients at the 1st paracentesis, after the
      reception of the laboratory results necessary to evaluate SAAG value. Randomization is
      stratified 1:1 according to SAAG values (≥ or &lt; to 11g/L) and Systemic treatment (yes or not)

        -  Patients randomized to arm A will be observed until the next episode requiring
           paracentesis (due to clinical symptoms : abdominal pain or heaviness, dyspnoea,
           orthopnoea, nausea/vomiting, anorexia, early satiety, gastro-oesophageal reflux, lower
           limb and genital oedema), at which time they will receive arm B (diuretics), in absence
           of contra-indication to diuretic treatment.

        -  Patients randomized to arm B will receive diuretics until the next episode requiring
           paracentesis, at which time they will receive arm A (observation).

      Patients will have a physical assessment within 24 hours prior to the start of treatment,
      once every two weeks for patients randomized in arm A and each week for patients randomized
      in arm B, at cross-over and at the end of the study. Patient will also have a biological
      assessment within 24 hours prior to the start of treatment, twice a week for patients
      randomized in arm B, at cross-over and at the end of the study. Finally, they will address a
      quality of life questionnaire (QLQ-C15-PAL) prior to the start of treatment, at cross-over
      and at the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time between symptomatic malignant ascites episodes requiring paracentesis</measure>
    <time_frame>Patients will be followed until their third malignant ascites episode, an expected average of 30 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>Up to 30 days after the last administration of the product</time_frame>
    <description>Adverse events and serious adverse events related to diuretic treatment according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life based on the EORTC (European Organization for Research and Treatment of Cancer) QLQ-C15-PAL</measure>
    <time_frame>At baseline (prior to the start of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life based on the EORTC (European Organization for Research and Treatment of Cancer) QLQ-C15-PAL</measure>
    <time_frame>At cross-over (approximately 15 days after inclusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life based on the EORTC (European Organization for Research and Treatment of Cancer) QLQ-C15-PAL</measure>
    <time_frame>At the end of the study (up to 6 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the patterns of prescription of diuretics</measure>
    <time_frame>During randomization in arm B (that is to say during approximately 15 days between the first and the second or between the second and the third milgnant ascites episode).</time_frame>
    <description>Growth pattern doses of diuretics, decrement pattern doses of diuretics, maintenance doses of diuretics, maximum doses reached of diuretics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response to diuretics : Serum Ascites Albumin Gradient (SAAG)</measure>
    <time_frame>Within 24 hours prior to the start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response to diuretics : renin aldosterone plasmatic level</measure>
    <time_frame>Within 24 hours prior to the start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response to diuretics : SAAG</measure>
    <time_frame>Twice a week for patients randomized in arm B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response to diuretics : renin aldosterone plasmatic level</measure>
    <time_frame>Twice a week for patients randomized in arm B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response to diuretics : SAAG</measure>
    <time_frame>At cross-over (approximately 15 days after inclusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response to diuretics : renin aldosterone plasmatic level</measure>
    <time_frame>At cross-over (approximately 15 days after inclusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response to diuretics : SAAG</measure>
    <time_frame>At the end of the study (up to 6 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response to diuretics : renin aldosterone plasmatic level</measure>
    <time_frame>At the end of the study (up to 6 months).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>A : observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Clinical monitoring and best supportive care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B : diuretics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone (+/- Furosemide)</intervention_name>
    <description>Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.</description>
    <arm_group_label>B : diuretics</arm_group_label>
    <other_name>Spiroctan</other_name>
    <other_name>Aldactone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced stage cancer

          -  First episode of malignant ascites

          -  Grade 2 or 3 ascites

          -  Clinically symptomatic ascites requiring paracentesis due to : abdominal pain or
             heaviness, dyspnoea, orthopnoea, nausea/vomiting, anorexia, early satiety,
             gastro-oesophageal reflux, lower limb and genital oedema

          -  Age ≥ 18 years

          -  Performance status ≤ 3

          -  Life expectancy ≥ 1 month

          -  Absence of contra-indication to diuretic treatment

          -  Patient regularly followed up by a palliative care or supportive care team

          -  Signed and dated informed consent

        Exclusion Criteria:

          -  Hepatic disorders : cirrhosis, hepatitis, hepatocellular insufficiency, hepatic
             encephalopathy

          -  Non malignant ascites

          -  Hydroelectrolytic disorders: hyponatremia (&lt; 130 mmol/L) or hyperkaliemia (&gt; 5 mmol/L)
             or severe hypokaliemia (&lt; 3 mmol/L)

          -  Functional acute renal insufficiency

          -  Urinary disorders : Obstruction in the urinary tract, Oliguria/anuria

          -  Chronic renal failure

          -  Patient unable to swallow

          -  Sulfamides allergy

          -  Hypersensitivity to spironolactone or to any of the excipients

          -  Hypersensitivity to furosemide or to any of the excipients

          -  Pregnant or breastfeeding women

          -  Patient under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent GAMBLIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent GAMBLIN, MD</last_name>
    <phone>+33(0)3 20 29 59 18</phone>
    <email>v-gamblin@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurélie THENOT-MARICOURT</last_name>
    <phone>+33(0)3 20 29 59 18</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Compiègne-Noyon</name>
      <address>
        <city>Compiègne</city>
        <zip>60321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence BIRKUI DE FRANCQUEVILLE, MD</last_name>
      <email>l.birkuidefrancqueville@ch-compiegnenoyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne Lucile SCHULZ, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Laurence BIRKUI DE FRANCQUEVILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Lucile SCHULZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Grande Synthe</name>
      <address>
        <city>Grande Synthe</city>
        <zip>59760</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François WUYDIN, MD</last_name>
      <email>f.wuydin@sfr.fr</email>
    </contact>
    <investigator>
      <last_name>François WUYDIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Licia TOUZET, MD</last_name>
      <email>licia.touzet@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Licia TOUZET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie DANEL-DELERUE, MD</last_name>
      <email>delerue.marie@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Marie DANEL-DELERUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain CHICQUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent GAMBLIN, MD</last_name>
      <email>v-gamblin@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent GAMBLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arlette DA SILVA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie VILLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume CARBONELLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle RODRIGUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean DANIS, MD</last_name>
      <email>jean.danis@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Jean DANIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole BOULEUC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyne REYNAULT TESSIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexis BURNOD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Jaurès</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia REVNIC, MD</last_name>
      <email>julia.revnic@hopitaljeanjaures.fr</email>
    </contact>
    <investigator>
      <last_name>Julia REVNIC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alix BONNIERES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine MARSAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth ALLOT-LAUWERS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale HAOND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estelle DESTREE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GH Diaconesses Croix St Simon</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane PICARD, MD</last_name>
      <email>spicard@hopital-dcss.org</email>
    </contact>
    <investigator>
      <last_name>Stéphane PICARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure COPEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Odile MARTINET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georges CZAPIUK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique KAROUI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marilène FILBET, MD, PhD</last_name>
      <email>marilene.filbet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marilène FILBET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elise PERCEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie DESSUS-CHEVREL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélanie PERRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie MUNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colombe TRICOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier DUBROEUCQ, MD</last_name>
      <email>Olivier.DUBROEUCQ@reims.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier DUBROEUCQ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane PERIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe GUILBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivien CECCATO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agnes HUTIN, MD</last_name>
      <email>a.hutin@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Agnes HUTIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estelle BOTTON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc PRACHT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel LE SOURD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien EDELINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie TALARMIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire LARIBLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanny LE DU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Roubaix</name>
      <address>
        <city>Roubaix</city>
        <zip>59056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katia HEBBAR, MD</last_name>
      <email>katia.hebbar@ch-roubaix.fr</email>
    </contact>
    <contact_backup>
      <last_name>Céline AFCHAIN, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Katia HEBBAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline AFCHAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Véronique FRASIE, MD</last_name>
      <email>vfrasie@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Véronique FRASIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dalando DIALLO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume BOUQUET, MD</last_name>
      <email>gbouquet@ch-tourcoing.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume BOUQUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie FLIPO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thérèse SAPIN-DELECLUYSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Vauban</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe THOMAZEAU, MD</last_name>
      <email>soins.palliatifs@polyclinique-vauban.com</email>
    </contact>
    <investigator>
      <last_name>Philippe THOMAZEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence VIGOURET-VIANT, MD</last_name>
      <email>laurence.vigouret-viant@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence VIGOURET-VIANT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine VOISIN-SALTIEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diuretic</keyword>
  <keyword>Malignant ascites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

